Tyrosine kinase inhibitorFDA-approvedSecond-line
Braftovi
Generic name: encorafenib
How it works
Encorafenib blocks the BRAF V600E mutation, a common genetic alteration in colorectal cancer.
Cancer types
Colorectal Cancer— BRAF V600E-mutated
Efficacy
Studies show that encorafenib can improve response rates and overall survival in patients with metastatic colorectal cancer harboring the BRAF V600E mutation.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Encorafenib Plus Binimetinib for Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Cost-effectiveness of cancer treatment in China questioned | Colorectal Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.